Reviewer’s report

Title: A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin

Version: 1 Date: 21 Jun 2017

Reviewer: Akinobu Nakamura

Reviewer's report:

The authors revised their manuscript according to the criticisms. There is, however, one point which should be addressed for publication in this journal.

Specific comments

Major points

Criticism 1: (Discussion) "The relative increase in body weight in the omarigliptin group compared to placebo may be due to the improvement in glycemic control and better metabolic status of the patients treated with omarigliptin." I do not understand this sentence. Why could the improvement in glycemic control and better metabolic status increase body weight? The phrase "better metabolic status" is too vague.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I have received speaker honoraria from Drug Companies Sanofi, Mitsubishi Tanabe Pharma, Daiichi Sankyo, Eli Lilly Japan, MSD, Novo Nordisk Pharma, Novartis Pharma, AstraZeneca, Takeda Pharmaceutical Co., LTD., Astellas, Kowa Pharmaceutical Co., LTD., Ono Co., LTD., Dainippon Sumitomo Pharma Co, Ltd, Nippon Boehringer Ingelheim Co, LTD, Kissei Pharmaceutical Co, LTD, and Taisho Toyama Pharmaceutical Co., LTD and obtained research support from Drug Companies Sanofi, Mitsubishi Tanabe Pharma, MSD, Novo Nordisk Pharma, Novartis Pharma, AstraZeneca, Ono Co., LTD., and Taisho Toyama Pharmaceutical Co., LTD.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal